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Abstract Transport of sialic acid through the lysosomal
membrane is defective in the human sialic acid storage disease.
The mammalian sialic acid carrier has a wide substrate
specificity for acidic monosaccharides. Recently, we showed that
also non-sugar monocarboxylates like L-lactate are substrates
for the carrier. Here we report that other organic anions, which
are substrates for carriers belonging to several anion transporter
families, are recognized by the sialic acid transporter. Hence, the
mammalian system reveals once more novel aspects of solute
transport, including sugars and a wide array of non-sugar
compounds, apparently unique to this system. These data suggest
that the search for the sialic acid storage disease gene can be
initiated by a functional selection of genes from a limited number
of anion transporter families. Among these, candidates will be
identified by mapping to the known sialic acid storage disease
locus.
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1. Introduction
Recent work has led to the characterization of speci¢c
transport systems for monosaccharides in the mammalian ly-
sosomal membrane [1,2]. One of these, the sialic acid trans-
porter has an essential metabolic function in the disposal of
acid sugars from the lysosomal compartment after degrada-
tion of glycoproteins, glycosaminoglycans and glycolipids. In
the human genetic disorders Salla disease and infantile sialic
acid storage disease (SASD) (OMIM 269920), the function of
this transporter is impaired and a progressive accumulation of
acid sugars occurs in the lysosomal compartment [3,4]. The
responsible SASD gene(s) is (are) not known but linkage was
demonstrated for both phenotypes to chromosome 6q14-q15
[5]. The lysosomal transporter from human ¢broblasts and rat
liver recognizes monocarboxylic anionic sugars (e.g. sialic
acid, glucuronic acid and iduronic acid) and other aliphatic
monocarboxylated anions (e.g. L-lactate), showing functional
similarities with the previously characterized family of mono-
carboxylate transporters (MCTs) [1,4,6].
Membrane transporters have been classi¢ed into distinct
families on the basis of sequence similarities [7]. Within each
family, most proteins have a similar substrate speci¢city, in-
dicating that substrate speci¢city frequently correlates with
phylogeny. In this way several di¡erent anion transporter
families have been characterized [8]. The MCT family seems
structurally and phylogenetically distinct from other families
of organic anion transporters. So far, the molecular structure
of the lysosomal sialic acid transporter is not known, but
initial functional characterization showed some similarities
with members of the di¡erent anion transporter families [6].
Therefore, in this paper we have compared in more detail the
functional properties of the lysosomal sialic acid transporter
with those of carriers from di¡erent families of anion trans-
porters. Our ¢nal aim is to identify and clone the sialic acid
transporter gene causing SASD, which can be initiated by this
functional approach.
2. Materials and methods
2.1. Materials
Rat liver lysosomes were isolated by di¡erential centrifugation, and
highly puri¢ed membrane vesicles were prepared as described [1]. The
lysosomal membrane vesicles were suspended at a protein concentra-
tion of 8^10 mg/ml in 20 mM NaHEPES, 0.1 mM EDTA at pH 7.4
and were stored at 370‡C. [3H]GlcA (speci¢c activity 6.6 Ci/mmol)
was purchased from Amersham Pharmacia Biotech. Most chemicals
were purchased from Sigma or as indicated.
2.2. Transport assays
For a ‘zero-trans’ uptake assay, lysosomal membrane vesicles were
rapidly thawed at 37‡C and pre-equilibrated for 10 min in 20 mM
NaHEPES, 10 mM KCl and 10 WM valinomycin at 20‡C. All uptake
studies were performed for 30 s at 20‡C and in the presence of an
inward-directed proton gradient (pHout = 5.56 pHin = 7.4) as de-
scribed earlier [4]. For cis-inhibition studies 10 Wl pre-equilibrated
vesicles were incubated with 10 Wl of substrate solution containing
0.5 WCi of radiolabelled GlcA (¢nal concentration 2.5 WM) in 20
mM NaHEPES, 80 mM Mes(free acid), resulting in a extravesicular
pH of 5.5 and 10 Wl of 21 mM of several organic anions (¢nal con-
centration 7 mM), titrated with NaOH to pH 5.5. The following
organic anions were used: K-ketoglutarate, p-aminohippurate, urate,
salicylate, valproate, methotrexate, folate, glutamate, tetraethylammo-
nium, phosphate, sulfate, D-glucosamine-2-sulfate, D-galactose-6-sul-
fate, D-glucose-6-phosphate, N-acetyl-glucosamine-1-phosphate. The
blank value was determined by incubation of vesicles with 7 mM
unlabelled GlcA and substracted from all determinations. Incubations
were stopped by the addition of 70 Wl of ice-cold stop-bu¡er (13 mM
NaHEPES, 27 mM Mes(free acid) and 10 mM KCl, pH 5.5) and 100
Wl was immediately applied to a Sephadex G50 ¢ne (Pharmacia Bio-
tech) column (Pasteur pipettes, 0.5U5 cm), equilibrated in cold stop-
bu¡er at 4‡C. Vesicles were eluted with 1 ml ice-cold stop-bu¡er.
Vesicle-associated radioactivity was determined by liquid scintillation
counting in 10 ml Instagel (Packard).
Trans-stimulation of [3H]GlcA uptake was studied at pHin =
pHout = 5.5 in the presence of the ionophore monensin. 15 Wl of
vesicles were pre-equilibrated 60 min at 20‡C with 40 mM Mes(free
acid), 12 mM NaHEPES, 4 mM KHEPES, 1 mM NaGlcA or other
organic anions, 10 WM valinomycin and 10 WM monensin (¢nal con-
centrations). The assay was started by adding 75 Wl of an equivalent
FEBS 21656 5-3-99
0014-5793/99/$20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 0 1 8 7 - 8
*Corresponding author. Fax: (31) (10) 4089489.
E-mail: verheijen@ikg.fgg.eur.nl
Abbreviations: GlcA, glucuronic acid; Neu5Ac, N-acetylneuraminic
acid, sialic acid; PAH, p-aminohippurate; TEA, tetraethylammonium;
GlcNH2-2-S, D-glucosamine-2-sulfate; Gal-6-S, D-galactose-6-sulfate;
Glu-6-P, D-glucose-6-phosphate; GlcNAc-1-P, N-acetylglucosamine-1-
phosphate
FEBS 21656 FEBS Letters 446 (1999) 65^68
bu¡er containing 2 WCi of radiolabelled GlcA (¢nal concentration
3 WM). Control experiments were performed by pre-equilibration of
the membranes with the same bu¡er without Na-GlcA or other or-
ganic anions. To give the same extravesicular substrate concentration
in both experiments, 0.25 mM unlabelled organic anion was added
together with radiolabelled substrate at the start of the assay.
For competitive inhibition studies, initial proton dependent trans-
port rates (30 s, 20‡C) of 10 WM [3H]GlcA were measured at increas-
ing unlabelled GlcA concentrations (0.05, 0.1, 0.2, 0.3, 0.5 and 1 mM
¢nal concentrations) in the presence or absence of di¡erent inhibitors.
Details about the used concentrations of inhibitors are described in
the legend. All experiments were performed in duplicate or triplicate.
3. Results
In earlier substrate speci¢city studies, we have shown that
the lysosomal sialic acid transporter recognizes structurally
di¡erent types of organic anions, like monocarboxylic (al-
donic, hexuronic and N-substituted anionic) sugars and ali-
phatic monocarboxylates [1,6]. Recent genome sequencing
data and a wealth of biochemical and molecular genetic in-
vestigations have revealed the occurrence of many families of
primary and secondary transporters [7,8]. Since in the lysoso-
mal system a proton gradient provides the driving force for
secondary active transport [1], transporter families in which
organic anions are known to be transported by a proton sym-
port mechanism are of special interest. In this paper, we in-
vestigated which other organic anions are recognized by the
lysosomal sialic acid transporter. We tested a variety of typ-
ical substrates of previously identi¢ed members of the di¡er-
ent families which transport organic anions. As representa-
tives of the novel multispeci¢c organic anion transporters
(OATs) we tested p-aminohippurate (PAH), K-ketoglutarate,
urate, salicylate, methotrexate, folate and valproate [9,10].
The dicarboxylate K-ketoglutarate is also a substrate of the
K-ketoglutarate:H symport permease of Escherichia coli,
which belongs to a di¡erent family [8]. Additionally, we tested
substrates of the mammalian inorganic anion transporters of
the sulfate permease (SulP) and phosphate:H symporter
(PHS) family (i.e. sulfate and phosphate) [11^13], of the acidic
amino acid transporter of the proton-dependent oligopeptide
transporter (POT) family (i.e. glutamate) [8,11], of the organic
cation transporters (OCTs) (i.e. tetraethylammonium) [14] and
of the bacterial hexose phosphate transporters of the organo-
phosphate:Pi antiporter (OPA) family (i.e. several sugar-phos-
phates) [15]. As shown in Fig. 1, the lysosomal sialic acid
transporter is strongly cis-inhibited by the dicarboxylate K-
ketoglutarate, the prototype substrate of organic anion trans-
porters PAH, the purine metabolism endproduct urate and
the acidic monocarboxylated drug salicylate. Moderate inhib-
ition (25^60% of control) was shown by the anti-epileptic drug
valproate and the anionic drugs methotrexate and folate. No
signi¢cant inhibition was found for the acidic amino acid
glutamate, the organic cation tetraethylammonium (TEA),
the inorganic anions phosphate and sulfate and sulfated or
phosphorylated sugars. This demonstrates that the lysosomal
sialic acid transporter recognizes di¡erent organic anions, but
not acidic amino acids, organic cations, inorganic anions or
sugar-phosphates.
In order to test which of the cis-inhibitors can be trans-
ported by the lysosomal sialic acid transporter, we investi-
gated their trans-stimulation e¡ect on the uptake of [3H]GlcA.
For these experiments, vesicles were pre-loaded with unla-
belled compound and the uptake of [3H]GlcA was measured
in the absence of a proton gradient. In our experience, sig-
ni¢cant trans-stimulation represents at least a two-fold in-
crease above the basal uptake rate under the current condi-
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Fig. 1. Cis-inhibition of [3H]GlcA uptake into lysosomal membrane
vesicles by di¡erent anions. Lysosomal membrane vesicles were pre-
equilibrated for 10 min, 20‡C in 20 mM NaHEPES, 10 mM KCl
and 10 WM valinomycin. A sample of 10 Wl pre-equilibrated vesicles
were incubated for 30 s at 20‡C with 2.5 WM [3H]GlcA in the pres-
ence of an inward-directed proton gradient and 7 mM of the indi-
cated compounds. The blank value was substracted from all deter-
minations. Data are presented as percentage of the uninhibited
transport activity. Values (n = 3) are mean þ S.D.
Table 1
Trans-stimulation of GlcA uptake by di¡erent anions
anionic compound Transport Activity
+Preloading 3Preloading Trans-stimulation factor
(pmol/mg/30 s)
GlcA 6.53 þ 0.28 0.99 þ 0.04 6.6
Neu5Ac 5.90 þ 0.07 0.84 þ 0.07 7.0
K-Ketoglutarate 4.35 þ 0.03 0.88 þ 0.07 4.9
PAH 2.53 þ 0.17 1.56 þ 0.03 1.6
Salicylate 1.87 þ 0.06 1.05 þ 0.16 1.8
Valproate 1.84 þ 0.09 1.16 þ 0.03 1.6
Methotrexate 1.94 þ 0.17 1.62 þ 0.05 1.2
Urate 2.09 þ 0.14 1.57 þ 0.07 1.3
Glutamate 1.74 þ 0.05 1.32 þ 0.17 1.3
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tions. As shown in Table 1, K-ketoglutarate clearly trans-
stimulated GlcA uptake, like GlcA itself and Neu5Ac. PAH,
salicylate, valproate, methotrexate, urate and glutamate did
not show a signi¢cant trans-stimulation at the tested concen-
trations. This indicates that the lysosomal sialic acid trans-
porter can exchange GlcA for K-ketoglutarate.
Further kinetic studies were performed to determine the
mode of inhibition. As shown in Fig. 2, all compounds in-
hibited in a concentration dependent manner. In subsequent
kinetic inhibition studies the following concentrations, close
to IC50, were used: 0.5 mM K-ketoglutarate, 1 mM PAH,
1 mM valproate, 5 mM urate and 5 mM folate. The initial
uptake of [3H]GlcA was measured at increasing GlcA concen-
trations in voltage clamped membranes with K/valinomycin
in the absence and presence of unlabelled compounds. As
illustrated in Fig. 3, all compounds showed a competitive
mode of inhibition of glucuronic acid transport. The calcu-
lated Ki for K-ketoglutarate, valproate and PAH were respec-
tively 0.46 mM, 0.64 mM and 0.73 mM (Ki = Kt[I]/{(-1/x)-Kt},
in which Kt is the Km for GlcA, [I] is the inhibitor concen-
tration, x is the intercept on the abscissa). For urate and
folate, we found a Ki of respectively 1.77 mM and 4.6 mM,
indicating that these last compounds have a much lower af-
¢nity for the transporter.
4. Discussion
The lysosomal sialic acid transporter shows functional sim-
ilarities with the MCT family [6]. Both, MCTs and our car-
rier, are energized by proton symport, have an overlap in
substrate speci¢city in compounds like L-lactate, and are sen-
sitive to speci¢c inhibitors like cyano-cinnamates. The MCT
family is classi¢ed as a subfamily of the major facilitator
superfamily (MFS) [7,8]. This superfamily contains many dif-
ferent prokaryotic and eukaryotic anion transporters. Many
homologues of bacterial genes have also been found in higher
animals (mammalians). Members of the MFS are transporting
small solutes, including sugars, often in response to ion gra-
dients and are recently classi¢ed into 18 distinct subfamilies
[8]. There can be signi¢cant overlap in substrate speci¢city
between members of the di¡erent subfamilies.
In the experiments, described in this paper, several sub-
strates of the OATs [9,10,16^18], like PAH, K-ketoglutarate,
folate and valproate showed competitive cis-inhibition of
GlcA uptake by the lysosomal sialic acid transporter. Trans-
stimulation studies demonstrated that K-ketoglutarate is not
only recognized but also actually translocated across the
membrane by the mammalian sialic acid transporter. The
OATs have homology with members of the sugar porter sub-
family of the MFS [16,18]. Better phylogenetic analysis could
reveal whether these transporters indeed belong to the sugar
porter family. This shows that our observation of a mam-
malian carrier for both sugars and anions is not completely
unexpected. We do not know whether compounds like K-
ketoglutarate, PAH, urate, salicylate or valproate are physio-
logical substrates in lysosomes or not. It would be interesting
to study in more detail the role of the sialic acid transporter in
the translocation of these drugs or their metabolites across the
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Fig. 2. Concentration dependent inhibition of [3H]GlcA uptake.
Transport of 10 WM [3H]GlcA was measured in the presence of K-
ketoglutarate (b), valproate (a), PAH (F), folate (R) and urate (v)
at the following concentrations: 100 WM, 1, 7 and 20 mM (plotted
on a logarithmic x-axis). Transport assays (n = 3) were performed as
described in the legend of Fig. 1. The blank value was substracted
from all determinations. The dotted line corresponds with 50% of
the uninhibited rate. The uninhibited rate is indicated on the y-axis
(b).
Fig. 3. Inhibition kinetics of [3H]GlcA transport by di¡erent anions.
Initial uptake rates of 10 WM [3H]GlcA (30 s, 20‡C) were measured
at increasing GlcA concentrations in the presence of a proton gra-
dient as described in the legend of Fig. 1. The uptake medium con-
tained the following inhibitors: (A) 0.5 mM K-ketoglutarate (a),
1 mM PAH (E) or 1 mM valproate (v). (B) 5 mM of folate (R) or
urate (+). As a control, the uptake medium contained no inhibitor
(b). The blank value was substracted from all determinations. Data
are plotted double reciprocally.
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lysosomal membrane in future experiments, in relation to Sal-
la disease.
K-Ketoglutarate is also a known substrate of a di¡erent
MFS family, the metabolite:H symporter (MHS) family
[8]. Substrates of these carriers all possess at least one carbox-
yl group and the carriers function as proton symporters.
Sialic acid is an important substrate of our transporter.
Two putative sialic acid permeases are known in the prokar-
yotes E. coli [19] and Haemophilus in£uenza. They form the
sialate:H symporter (SHS) family [8]. Interestingly, the yeast
Saccharomyces cerevisiae homologue (JEN1) of the E. coli
permease [20], although functionally characterized as a car-
boxylic acid transport protein (lactate transport, [21]), was
classi¢ed on the basis of sequence similarities as a member
of this SHS family.
The hexuronate glucuronic acid is another main substrate
of the lysosomal sialic acid transporter. Few other transport-
ers for hexuronates and glucarate (saccharate) are known.
They belong to the anion:cation symporter (ACS) family of
the MFS [8]. Saccharic acid 1,4 and 3,6 lactons are strong cis-
inhibitors of GlcA transport by the lysosomal sialic acid
transporter [22]. The lysosomal sialic acid transporter is the
only mammalian carrier known to transport free hexuronates
like glucuronate, galacturonate and iduronate [1,6].
The aldonic acid sugars gluconate and galactonate are also
recognized by our transport protein [1]. They are substrates of
the recently identi¢ed gluconate:H symporter family (GntP),
which is not a member of the MFS [23].
The tested compounds methotrexate and folate are known
substrates of another phylogenetic di¡erent superfamily, dis-
tinct from the MFS, called the organic anion transporting
polypeptides (oatps) [24,25]. As shown in Fig. 1, methotrexate
and folate mildly inhibited GlcA transport, with a very high
Ki for folate. Since the oatps do not recognize PAH and K-
ketoglutarate and the lysosomal sialic acid transporter does
not seem to transport or recognize with a high a⁄nity sub-
strates like methotrexate and folate, it is very unlikely that our
transporter belongs to this family. Since sulfate, phosphate,
glutamate, tetraethylammonium and several sugar-phosphates
are not recognized by the lysosomal sialic acid transporter
(cis-inhibition studies), the SulP family [11,12], the PHS fam-
ily [11,13], the POT family [8,11], the OCT family [14] and the
OPA family [15] are not of particular interest to us.
With the present studies we intended to extend the knowl-
edge on the function of the lysosomal sialic acid carrier which
can be helpfull in the identi¢cation of the transporter gene
involved in SASD. Our recent biochemical studies suggested
homology between this transporter and the monocarboxylate
transporters, belonging to the MCT family. Here we present
data which show functional similarities with K-ketoglutarate
transporters within the OAT and MHS family. On its func-
tional basis, the transporter could also belong to the SHS,
ACS or GntP family. This means that the search for the
human sialic acid transporter gene should not be limited to
members of the MCT family.
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